CA Atra (All-trans Retinoic Acid) 10 mg Tablets contain All-trans Retinoic Acid (ATRA), a derivative of Vitamin A. It is used primarily in the treatment of acute promyelocytic leukemia (APL), a form of cancer that affects the bone marrow and blood. ATRA works by promoting the differentiation of abnormal cells into normal cells and inhibiting the growth of cancer cells. It is also used in the treatment of other skin conditions, such as keratinization disorders.

• Treats Acute Promyelocytic Leukemia (APL) by inducing differentiation and apoptosis of cancerous cells

• Promotes cell differentiation and prevents the growth of abnormal cancer cells

• Effective in skin conditions such as keratosis and acne vulgaris

• Offers an oral treatment option, improving convenience for long-term therapy

• Can be used in combination with other chemotherapy drugs for enhanced efficacy

• Dosage: The typical starting dose is 10 mg once or twice a day, depending on the doctor’s prescription and the patient’s condition

• The tablet should be swallowed whole with water. It should not be chewed, crushed, or split

• Take with food or as directed by your healthcare provider

• Adhere to the prescribed dosage schedule and never exceed the recommended dose

• Regular monitoring and follow-up with your healthcare provider are essential during treatment

• Active Ingredient: All-trans Retinoic Acid (10 mg per tablet)

• Recommended Dose: 10 mg once or twice daily

• Administration: Oral, with or without food

• Duration of Therapy: Depends on individual response and doctor’s instructions

• Follow-up Care: Regular blood tests and monitoring are recommended to track progress and identify side effects

• Pregnancy Category X: CA Atra should not be used during pregnancy as it can cause severe birth defects

• Monitor liver function regularly as All-trans Retinoic Acid may affect liver health

• Avoid alcohol during treatment to minimize liver strain

• Not recommended for children under a certain age; consult a healthcare provider

• Liver Function Tests: Regular tests are necessary to monitor liver enzymes and assess any possible liver damage

• Retinoid Toxicity: Prolonged use of high doses may lead to retinoid toxicity, which includes symptoms like headaches, dizziness, nausea, and dry skin

• Common: Dry skin, headache, dizziness, nausea, fatigue, muscle pain

• Less Common: Hair loss, vision changes, loss of appetite, mouth sores, joint pain

• Serious: Liver toxicity (yellowing of the skin or eyes, abdominal pain), vision problems (blurred vision, night blindness), signs of retinoid toxicity (severe headache, vomiting, changes in mood)

• Seek immediate medical help if you experience severe or persistent side effects, especially liver or vision problems

• Store at room temperature between 20°C and 25°C

• Keep the bottle tightly closed and store it in a dry place away from moisture and light

• Do not store in the bathroom or near the kitchen sink

• Keep out of reach of children

• Dispose of any unused medication according to local disposal guidelines

Q1. What is CA Atra used for?
A: CA Atra is used primarily in the treatment of acute promyelocytic leukemia (APL) and is also used in the treatment of certain skin conditions, such as acne and keratosis.

Q2. How should I take CA Atra?
A: Take 10 mg once or twice daily, as prescribed by your doctor. The tablet should be swallowed whole with water, and it can be taken with or without food.

Q3. Can CA Atra be used during pregnancy?
A: No, CA Atra should not be used during pregnancy as it is known to cause birth defects. If you are pregnant or planning to become pregnant, inform your doctor immediately.

Q4. Are there any dietary restrictions while taking CA Atra?
A: No specific dietary restrictions are required; however, it is advisable to avoid alcohol during treatment, as it can affect liver function and increase the risk of side effects.

Q5. How long do I need to take CA Atra?
A: The duration of treatment depends on your condition and the response to therapy. Follow your healthcare provider’s guidance on the length of treatment.